UK The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma giant; CDMO Sterling’s latest acquisition; and calls for a national registry to capture company payments to clinicians and patient support groups. The 30 fastest-growing unquoted pharma companies in the UK (Consultancy.uk)…
Turkey The shockwaves from the UK’s exit from the European Union have resounded across the continent, including in Turkey, where the country’s pharmaceutical and medical devices regulator has had to adjust its guidance on CE-mark certified devices. Leading lawyers from top Turkish law firm and PharmaBoardroom legal partner Moroğlu Arseven explain…
Europe Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler of Sanofi R&D looks at the future of European pharma post-Brexit, with the UK diverging from the rest of the continent in regulatory terms and the launch of the European Commission’s Pharmaceutical Strategy for Europe. After four…
UK When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left behind in terms of alignment with the world’s top regulatory bodies. Perhaps cognizant of this, the UK regulatory agency for…
UK The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed by the UK pharma industry, which counts Japan as its third largest export destination. However, with the Japanese government having previously expressed concern about uncertainties arising from the Brexit…
UK US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central London, with plans to open the ‘London Discovery Research Centre’ by 2025. Having announced that the hub would be built in 2017, one year after the UK’s vote…
UK Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British Prime Minister Boris Johnson’s sweeping election victory on a promise to “Get Brexit Done”. The UK now enters an 11-month transition period to disentangle political and economic ties from a single…
UK Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry’s third-best year on record. The UK’s exit from the European Union looms large over all British industries, including pharmaceuticals and biotech. Unsurprisingly, therefore, UK…
France As the UK prepares to leave the European Union in March 2019, stakeholders across the European life sciences industry are busy preparing for Brexit’s potential impact on their operations. In France, the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) – the country’s drug regulator –…
UK Yesterday, pharma giant AstraZeneca announced that they have halted investment in the UK due to lack of clarity on trading regulations during this time of Brexit uncertainty. “If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest,” Leif…
UK There is much debate surrounding the potential impact on the UK’s life sciences industry of the country’s decision to leave the European Union. Here, IQVIA analysis posits ‘upside’ and ‘downside’ Brexit scenarios on pharmaceutical market sales and growth in the UK in comparison to a theoretical ‘No Brexit’ scenario. Different…
brexit Last week, Roche Boss Severin Schwan expressed concern that Brexit could further slow the UK drug approval process. After the UK’s recent divorce from the EMA, officials are in unknown territory. With only six months until the UK leaves the EU, the UK government has advised drug makers to stockpile…
See our Cookie Privacy Policy Here